CYP2R1: A Drug Target / Disease Biomarker (G120227)

Target Name: CYP2R1

NCBI ID: G120227

CYP2R1

CYP2R1: A Drug Target / Disease Biomarker

CYP2R1, also known as CYP2R1B, is a gene that encodes for a protein known as the CYP2R1 enzyme. The CYP2R1 enzyme is a key player in the metabolism of many drugs, including many statins, antidepressants, and benzodiazepines. As a result, CYP2R1 has become a drug target of interest for many pharmaceutical companies due to its potential role in drug metabolism.

The CYP2R1 enzyme is a member of the cytochrome P450 (CYP) family, which is responsible for the metabolism of a wide variety of drugs. The CYP2R1 enzyme is primarily expressed in the liver and other organs and is responsible for metabolizing a wide range of drugs, including many statins, antidepressants, and benzodiazepines.

One of the key challenges in the use of these drugs is their potential interactions with other drugs or with certain genetic traits. For example, some people with certain genetic variations in the CYP2R1 gene may have altered levels of the CYP2R1 enzyme, leading to increased or decreased metabolism of certain drugs. This can result in the accumulation of these drugs in the body and an increased risk of side effects or toxicity.

To address this challenge, researchers have been studying the CYP2R1 gene and its role in drug metabolism. They have identified a number of potential drug targets that can be targeted with drugs or other therapies to modulate the activity of the CYP2R1 enzyme. These targets include the CYP2R1A, CYP2R1B, and CYP2R1C genes, which encode for proteins that are involved in the metabolism of different drugs.

One of the most promising drug targets for CYP2R1 is the CYP2R1B gene, which encodes for a protein that is involved in the metabolism of many statins, including atorvastatin, simvastatin, and rosuvastatin. Researchers have identified a number of potential drug compounds that can modulate the activity of the CYP2R1B protein, including inhibitors of CYP2R1B inhibitors and activators of CYP2R1B activators. These drugs have the potential to reduce the risk of statin-induced muscle damage and other potential side effects associated with these drugs.

Another promising drug target for CYP2R1 is the CYP2R1A gene, which encodes for a protein that is involved in the metabolism of many drugs, including amitriptyline, diltiazem, and verapamil. Researchers have identified a number of potential drug compounds that can modulate the activity of the CYP2R1A protein, including inhibitors of CYP2R1A inhibitors and activators of CYP2R1A activators. These drugs have the potential to reduce the risk of these drugs' side effects and improve their effectiveness.

In addition to these drug targets, researchers are also studying the CYP2R1 gene and its role in drug metabolism in a broader sense. They are interested in understanding how genetic variations in the CYP2R1 gene may affect drug responses to different drugs and how these variations may be used to develop more targeted therapies. They are also interested in studying the role of the CYP2R1 enzyme in other aspects of drug metabolism, such as its role in the metabolism of herbal remedies or natural products.

Overall, the CYP2R1 gene is a promising drug target for the development of new drugs and therapies. While further research is needed to fully understand its role in drug metabolism, it is clear that it is an important target for the development of more effective and

Protein Name: Cytochrome P450 Family 2 Subfamily R Member 1

Functions: A cytochrome P450 monooxygenase involved in activation of vitamin D precursors. Catalyzes hydroxylation at C-25 of both forms of vitamin D, vitamin D(2) and D(3) (calciol) (PubMed:12867411, PubMed:15465040, PubMed:18511070). Can metabolize vitamin D analogs/prodrugs 1alpha-hydroxyvitamin D(2) (doxercalciferol) and 1alpha-hydroxyvitamin D(3) (alfacalcidol) forming 25-hydroxy derivatives (PubMed:15465040, PubMed:18511070). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:12867411, PubMed:15465040, PubMed:18511070)

The "CYP2R1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP2R1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets